| Schedule of Segment Reporting Information, by Segment [Table Text Block] |
| |
|
Quarter Ended |
|
|
Six Months Ended |
|
| |
|
December 31, |
|
|
December 31, |
|
| |
|
2019 |
|
|
2018 |
|
|
2019 |
|
|
2018 |
|
| Net sales: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Protein Sciences |
|
$ |
141,517 |
|
|
$ |
135,462 |
|
|
$ |
282,512 |
|
|
$ |
261,852 |
|
| Diagnostics and Genomics |
|
|
43,846 |
|
|
|
39,263 |
|
|
|
86,397 |
|
|
|
76,010 |
|
| Intersegment |
|
|
(429 |
) |
|
|
(215 |
) |
|
|
(732 |
) |
|
|
(382 |
) |
| Consolidated net sales |
|
$ |
184,934 |
|
|
$ |
174,510 |
|
|
$ |
368,177 |
|
|
$ |
337,480 |
|
| Operating income: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Protein Sciences |
|
$ |
60,872 |
|
|
$ |
58,951 |
|
|
$ |
120,410 |
|
|
$ |
113,565 |
|
| Diagnostics and Genomics |
|
|
975 |
|
|
|
(1,054 |
) |
|
|
1,875 |
|
|
|
1,482 |
|
| Segment operating income |
|
$ |
61,847 |
|
|
$ |
57,897 |
|
|
$ |
122,285 |
|
|
$ |
115,047 |
|
| Costs recognized on sale of acquired inventory |
|
|
- |
|
|
|
(935 |
) |
|
|
- |
|
|
|
(1,869 |
) |
| Amortization of acquisition related intangible assets |
|
|
(15,108 |
) |
|
|
(15,002 |
) |
|
|
(30,008 |
) |
|
|
(29,278 |
) |
| Acquisition related expenses |
|
|
881 |
|
|
|
(348 |
) |
|
|
(429 |
) |
|
|
(2,973 |
) |
| Stock based compensation |
|
|
(10,618 |
) |
|
|
(6,861 |
) |
|
|
(19,418 |
) |
|
|
(18,426 |
) |
| Corporate general, selling, and administrative expenses |
|
|
(12 |
) |
|
|
(1,148 |
) |
|
|
(2,113 |
) |
|
|
(3,137 |
) |
| Consolidated operating income |
|
$ |
36,992 |
|
|
$ |
33,603 |
|
|
$ |
70,317 |
|
|
$ |
59,364 |
|
|